No insider purchase over the last 90 days. The latest was filed 15 May 2024.
Headquartered in Seattle, United States, Trupanion, Inc. belongs to the Banks sector and traces its origins to 1999. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 167 filings came from 16 insiders.
There is no open-market purchase to report; the filings show 18 sales worth €1.1M by 4 insiders. The largest single trade was a sale of €192k by Gallagher John R, published on 1 December 2025.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 167 filings here. Our records for Trupanion, Inc. go back to 2016, with 4 purchases and 130 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 1.44 bn USD.
Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
In the same sector, recent insider purchases at First Guaranty Bancshares, Inc. and Avidia Bancorp, Inc. also feature in our signals. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
+3 other insiders
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analysts rate Trupanion, Inc. Buy (bullish), based on 4 analysts. Average price target: US$33.25.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
FY ended December 2025 · cache
25 of 707 declarations
Trupanion, Inc. (NASDAQ: TRUP) is a specialized pet medical insurance company focused on cats and dogs. It is a United States-based public company listed on the NASDAQ market, founded in 2000 and headquartered in Seattle, Washington, United States. For investors, Trupanion should be viewed as a niche insurance platform operating at the intersection of animal health, claims data, and veterinary services rather than as a broad-based multiline insurer. The company describes itself as a leader in medical insurance for cats and dogs across the United States, Canada, and certain countries in Continental Europe, with more than 1 million pets currently enrolled according to its recent corporate communications. Its model is data-driven and vertically integrated, allowing it to price policies according to each pet’s characteristics and selected coverage level. Trupanion’s flagship offering is a lifetime pet medical insurance product with unlimited payouts on eligible expenses, which is a key differentiator in a market where pet owners are increasingly sensitive to veterinary inflation and rising treatment costs. One of the company’s most distinctive competitive advantages is its patented process that enables direct payment to veterinarians in seconds at checkout, reducing friction for both pet owners and veterinary clinics. This checkout technology helps support Trupanion’s positioning with veterinary partners and strengthens its ecosystem around the point of care. Commercially, the company relies on a mix of direct-to-consumer acquisition, veterinary partnerships, breeder and shelter relationships, affiliate channels, and other distribution initiatives. Recent public disclosures and press releases have highlighted strong growth in specialty veterinary care claims and materially higher average claim amounts in several specialties, underscoring the continuing inflation in animal healthcare costs and the increasing importance of insurance coverage. In 2025 and early 2026, Trupanion continued to emphasize its long-term growth strategy, its recurring-revenue membership base, and its geographic expansion beyond the core U.S. market. For equity investors, TRUP offers exposure to a secular theme: rising pet healthcare adoption and broader insurance penetration in animal health. At the same time, the investment case remains tied to underwriting discipline, claims trends, customer acquisition efficiency, and the company’s ability to maintain pricing power while scaling its membership base.
Purchases our model currently ranks for the recommendations list.
All recommendationsInsider filings
Over the last 90 days, 91 filings published between 28 July and 13 October 2026: 8 sales for €350k. 83 other filings (not open-market purchases or sales: grants, options, plans, sale notices, block transfers). Largest amounts: Qureshi Fawwad (Chief Financial Officer), sales of €157k; GALLAGHER JOHN R (Chief Operating Officer), sales of €110k; Tooth Margaret (CEO), sales of €83k.
Summary written automatically from public filings, without human review. General information, identical for every reader: it is not investment advice or a recommendation to buy or sell. Investing involves a risk of capital loss. Generated on 14 October 2026 (UTC)
Headquarters: Seattle, United States · Founded: 1999 · Wikipedia article
Source: Wikidata (CC0).
| Fiscal year end | Revenue | Net income | Diluted EPS | Filing |
|---|---|---|---|---|
| Dec 2025 | 1.44 bn USD | n.d. | 0.45 USD | 10-K |
| Dec 2024 | 1.29 bn USD | n.d. | -0.23 USD | 10-K |
| Dec 2023 | 1.11 bn USD | n.d. | -1.08 USD | 10-K |
| Dec 2022 | 905.2 m USD | n.d. | -1.10 USD | 10-K |
| Dec 2021 | 699.0 m USD | n.d. | -0.89 USD | 10-K |
Amounts in USD, as filed (forms 10-K, 20-F or 40-F). Source: SEC EDGAR.